BEAM
Price
$28.14
Change
+$0.37 (+1.33%)
Updated
Dec 24 closing price
Capitalization
2.86B
67 days until earnings call
Intraday BUY SELL Signals
BMRN
Price
$60.16
Change
-$0.98 (-1.60%)
Updated
Dec 24 closing price
Capitalization
11.56B
61 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BEAM vs BMRN

Header iconBEAM vs BMRN Comparison
Open Charts BEAM vs BMRNBanner chart's image
Beam Therapeutics
Price$28.14
Change+$0.37 (+1.33%)
Volume$430.29K
Capitalization2.86B
BioMarin Pharmaceutical
Price$60.16
Change-$0.98 (-1.60%)
Volume$1.21M
Capitalization11.56B
BEAM vs BMRN Comparison Chart in %
View a ticker or compare two or three
VS
BEAM vs. BMRN commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Buy and BMRN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (BEAM: $28.14 vs. BMRN: $60.16)
Brand notoriety: BEAM and BMRN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 20% vs. BMRN: 37%
Market capitalization -- BEAM: $2.86B vs. BMRN: $11.56B
BEAM [@Biotechnology] is valued at $2.86B. BMRN’s [@Biotechnology] market capitalization is $11.56B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 1 FA rating(s) are green whileBMRN’s FA Score has 0 green FA rating(s).

  • BEAM’s FA Score: 1 green, 4 red.
  • BMRN’s FA Score: 0 green, 5 red.
According to our system of comparison, BEAM is a better buy in the long-term than BMRN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 5 TA indicator(s) are bullish while BMRN’s TA Score has 5 bullish TA indicator(s).

  • BEAM’s TA Score: 5 bullish, 5 bearish.
  • BMRN’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, BMRN is a better buy in the short-term than BEAM.

Price Growth

BEAM (@Biotechnology) experienced а +9.92% price change this week, while BMRN (@Biotechnology) price change was +16.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.88%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was +55.39%.

Reported Earning Dates

BEAM is expected to report earnings on Mar 03, 2026.

BMRN is expected to report earnings on Feb 25, 2026.

Industries' Descriptions

@Biotechnology (+2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BMRN($11.6B) has a higher market cap than BEAM($2.86B). BEAM YTD gains are higher at: 13.468 vs. BMRN (-8.474). BMRN has higher annual earnings (EBITDA): 772M vs. BEAM (-434.55M). BMRN has more cash in the bank: 1.48B vs. BEAM (1.08B). BEAM has less debt than BMRN: BEAM (151M) vs BMRN (604M). BMRN has higher revenues than BEAM: BMRN (3.09B) vs BEAM (55.7M).
BEAMBMRNBEAM / BMRN
Capitalization2.86B11.6B25%
EBITDA-434.55M772M-56%
Gain YTD13.468-8.474-159%
P/E RatioN/A22.36-
Revenue55.7M3.09B2%
Total Cash1.08B1.48B73%
Total Debt151M604M25%
FUNDAMENTALS RATINGS
BEAM vs BMRN: Fundamental Ratings
BEAM
BMRN
OUTLOOK RATING
1..100
2635
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
70
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9774
PRICE GROWTH RATING
1..100
4049
P/E GROWTH RATING
1..100
10092
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BEAM's Valuation (33) in the null industry is somewhat better than the same rating for BMRN (70) in the Biotechnology industry. This means that BEAM’s stock grew somewhat faster than BMRN’s over the last 12 months.

BEAM's Profit vs Risk Rating (100) in the null industry is in the same range as BMRN (100) in the Biotechnology industry. This means that BEAM’s stock grew similarly to BMRN’s over the last 12 months.

BMRN's SMR Rating (74) in the Biotechnology industry is in the same range as BEAM (97) in the null industry. This means that BMRN’s stock grew similarly to BEAM’s over the last 12 months.

BEAM's Price Growth Rating (40) in the null industry is in the same range as BMRN (49) in the Biotechnology industry. This means that BEAM’s stock grew similarly to BMRN’s over the last 12 months.

BMRN's P/E Growth Rating (92) in the Biotechnology industry is in the same range as BEAM (100) in the null industry. This means that BMRN’s stock grew similarly to BEAM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BEAMBMRN
RSI
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
54%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
71%
Momentum
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
59%
MACD
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 3 days ago
63%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
56%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
53%
Advances
ODDS (%)
Bullish Trend 5 days ago
76%
Bullish Trend 8 days ago
58%
Declines
ODDS (%)
Bearish Trend 10 days ago
85%
Bearish Trend 16 days ago
62%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
63%
Aroon
ODDS (%)
Bearish Trend 3 days ago
81%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
BEAM
Daily Signal:
Gain/Loss:
BMRN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IYK67.330.35
+0.52%
iShares US Consumer Staples ETF
EVUS32.360.13
+0.40%
iShares ESG Aware MSCI USA Value ETF
KMID24.760.03
+0.14%
Virtus KAR Mid-Cap ETF
FHYS23.430.03
+0.11%
Federated Hermes Short Duration HY ETF
CPSA26.94N/A
N/A
Calamos S&P 500 Str Alt Prt ETF-Aug

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
+1.33%
CRSP - BEAM
71%
Closely correlated
+0.44%
RXRX - BEAM
61%
Loosely correlated
+0.92%
NTLA - BEAM
61%
Loosely correlated
+1.80%
PRME - BEAM
59%
Loosely correlated
-3.25%
AXON - BEAM
57%
Loosely correlated
+0.02%
More

BMRN and

Correlation & Price change

A.I.dvisor indicates that over the last year, BMRN has been loosely correlated with FOLD. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if BMRN jumps, then FOLD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMRN
1D Price
Change %
BMRN100%
-1.60%
FOLD - BMRN
58%
Loosely correlated
+0.28%
TECH - BMRN
50%
Loosely correlated
-0.10%
REGN - BMRN
44%
Loosely correlated
-0.19%
ORKA - BMRN
43%
Loosely correlated
+1.29%
BEAM - BMRN
42%
Loosely correlated
+1.33%
More